Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
141.7 EUR | -4.90% | -6.31% | -10.06% |
Apr. 24 | IMCD's Spanish Unit to Buy Cobapharma | MT |
Mar. 27 | IMCD's Benelux Arm to Purchase Gova Ingredients | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The firm trades with high earnings multiples: 26.74 times its 2024 earnings per share.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.06% | 8.61B | A- | ||
+28.72% | 1.01B | - | ||
+8.23% | 173M | - | - | |
+36.99% | 143M | - | - | |
+4.24% | 115M | - | - | |
-4.88% | 99.64M | - | - | |
+7.15% | 87.9M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IMCD Stock
- Ratings IMCD N.V.